Shionogi strikes deal following Japan dolutegravir filing
This article was originally published in Scrip
Shionogi has entered into an agreement to co-promote in Japan the integrase strand transfer inhibitor (ISTI) for HIV dolutegravir, rekindling its participation in a molecule that it originally co-developed.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.